1. Home
  2. SBGI vs EVO Comparison

SBGI vs EVO Comparison

Compare SBGI & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$14.64

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.65

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBGI
EVO
Founded
1986
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
SBGI
EVO
Price
$14.64
$3.65
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$21.00
$7.00
AVG Volume (30 Days)
395.5K
255.2K
Earning Date
02-25-2026
11-05-2025
Dividend Yield
6.63%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,337,000,000.00
$887,396,457.00
Revenue This Year
N/A
N/A
Revenue Next Year
$10.36
$8.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.89
$2.84
52 Week High
$17.88
$4.80

Technical Indicators

Market Signals
Indicator
SBGI
EVO
Relative Strength Index (RSI) 40.07 71.15
Support Level $14.98 $3.10
Resistance Level $15.50 $3.23
Average True Range (ATR) 0.46 0.08
MACD -0.11 0.07
Stochastic Oscillator 6.58 98.73

Price Performance

Historical Comparison
SBGI
EVO

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: